Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2005 Jun;91(6):825-31.
doi: 10.1136/hrt.2004.053991.

Endothelin antagonism in pulmonary hypertension, heart failure, and beyond

T Attinà  1 , R Camidge, D E Newby, D J Webb
Affiliations
Review

Endothelin antagonism in pulmonary hypertension, heart failure, and beyond

T Attinà et al. Heart. 2005 Jun.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Factors regulating the synthesis of endothelin-1 (ET-1). ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; CNP, C type natriuretic peptide; IL-1, interleukin-1; LDL, low density lipoprotein; TGF, tissue growth factor.
Figure 2
Figure 2
Schematic representation of endothelin-1 (ET-1) actions. AVP, arginine vasopressin; GFR, glomerular filtration rate; RPF, renal plasma flow.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–5. ▸ This is the original landmark report of the discovery of endothelin-1, including the isolation and sequencing of the peptide, identification of the gene sequence for its generation, and the pathway of production. This paper also highlights the vascular pharmacology and the pivotal role of ET-1 in vasoconstriction and hypertension. - PubMed
    1. Haynes WG, Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 1998;16:1081–98. - PubMed
    1. Benigni A, Remuzzi G. Endothelin antagonists. Lancet 1999;353:133–8. ▸ A concise review on endothelin antagonists and their use in experimental and initial clinical studies. - PubMed
    1. Kedzierski RM, Yanagisawa M. Endothelin system: the double-edged sword in health and disease. Ann Rev Pharmacol Toxicol 2001;41:851–76. ▸ A comprehensive and updated review highlighting the involvement of endothelin-1 in the pathophysiology of cardiovascular disease. - PubMed
    1. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994;344:852–4. ▸ An important early clinical study showing the involvement of endothelin-1 in the maintenance of basal vascular tone. - PubMed

MeSH terms